Clinical Trial

A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
Trial Details
NCT Number NCT07107373
Lead Sponsor Bristol-Myers Squibb
Conditions Obstructive Hypertrophic Cardiomyopathy (oHCM)
Enrollment 150 participants
Start Date 2023-12-22
Primary Completion 2024-07-26 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-06